Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31547778 | 0.98 | TDP1 (0.75) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL5864330 | 0.98 | TDP1 (0.75) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL86384 | 0.89 | TDP1 (0.72) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL6442808 | 0.88 | TDP1 (1.00) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL6851027 | 0.87 | TDP1 (0.70) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL8654324 | 0.86 | TDP1 (0.68) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL14851019 | 0.85 | TDP1 (0.78) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL30294105 | 0.84 | TDP1 (0.84) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL9814242 | 0.84 | TDP1 (0.84) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL3161153 | 0.84 | TDP1 (0.84) | TDP1EGLN3LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119451277-A | Cleaning method and texturing method of solar cell texturing cleaning tank | 晋能光伏技术有限责任公司 | 2025-02-14 | — | — | CN | claimed |
| EP-1802572-B1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-22 | — | — | EP | claimed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | claimed |
| JP-6329640-A | — | — | None | — | — | JP | disclosed |
| EP-3418289-B1 | ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE, AND ARTIFICIAL OLIGONUCLEOTIDE | INST OF SCIENCE TOKYO (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4680236-A2 | 3-ALKYLAMINE INDOLE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4681712-A2 | PROCESS FOR THE PRODUCTION OF FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4126854-B1 | PROCESS FOR THE PRODUCTION OF FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| US-5436262-A | Pharmacologically active derivatives of 2-(benzimidazol-2-yl)-1,3-diaminopropane | DOMPE FARMACEUTICI SPA (IT) | 1995-07-25 | — | — | US | disclosed |
| EP-0630889-A1 | Pharmacologically active derivatives of 2-(benzimidazol-2-yl)-1,3-diaminopropane | DOMPE' FARMACEUTICI S.p.A. (IT) | 1994-12-28 | — | — | EP | disclosed |
| JP-H06329640-A | PHARMACOLOGICALLY ACTIVE DERIVATIVE OF 2-(BENZIMIDAZOLE-2-YL)-1,3-DIAMINOPROPANE | DOMPE FARMACEUT SPA | 1994-11-29 | — | — | JP | disclosed |
| US-4434174-A | Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1984-02-28 | — | — | US | disclosed |
| US-4363808-A | N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1982-12-14 | — | — | US | disclosed |
| EP-0034116-A2 | N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1981-08-19 | — | — | EP | disclosed |
| US-4264494-A | Chromium complex dyestuffs for natural polyamides and synthetic nylons | BASF AKTIENGESELLSCHAFT (DE) | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | TDP1 3388/4885EGLN3 2598/4885LMNA 3037/4885 |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCY5 | TDP1 857/4885EGLN3 972/4885LMNA 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.